Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy

Sanaz Naghizadeh, Ali Mohammadi, Behzad Baradaran, Behzad Mansoori

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Abstrakt

Among cancers, lung cancer is the most morbidity and mortality disease that is remaining the fatalist. Generally, there are multiple treatment procedures for lung cancer, such as surgery, immunotherapy, radiotherapy and chemotherapy. There is, therefore, an urgent need for more specified and efficient methods for treatment of lung cancer such as RNAi, which in combination with traditional therapies could silence genes that are involved in the drug resistance. These genes may either be motivators of apoptosis inhibition, EMT and DNA repair system promoters or a member of intracellular signaling pathways, such as JAK/STAT, RAS/RAF/MEK, PI3K/AKT, NICD, B-catenin/TCF/LEF and their stimulator receptors including IGFR, EGFR, FGFR, VEGFR, CXCR4, MET, INTEGRINS, NOTCH1 and FRIZZLED, so could be considered as appropriate targets. In current review, the results of multiple studies which have employed drug application after one specific gene silencing or more than one gene from distinct pathways also simultaneous drug and RNAi usage in vitro and in vivo in lung cancer were summarized.

OriginalsprogEngelsk
Artikelnummer143972
TidsskriftGene
Vol/bind714
Antal sider11
ISSN0378-1119
DOI
StatusUdgivet - 25. sep. 2019

    Fingerprint

Bibliografisk note

Copyright © 2019. Published by Elsevier B.V.

Citationsformater